{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-23-002225","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.302927+00:00","generated_at":"2026-06-13T22:37:31.514176+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Chemomab Therapeutics discloses CFO compensation: $260K salary, 45% bonus, 102,860 ADS options at $1.70","bullets":["Annual base salary of $260,000 for new CFO Sigal Fattal, plus customary social benefits.","Yearly bonus potential of 45% of base salary, based on mutually agreed objectives subject to Compensation Committee approval.","Grant of options to purchase 102,860 American Depositary Shares at $1.70 per ADS, vesting over 4 years.","Options accelerate upon a change in control (CIC); exercise period extended to 12 months post-termination (except for Cause)."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-23-002225","json":"https://secwatch.observer/filing/0001178913-23-002225.json","markdown":"https://secwatch.observer/filing/0001178913-23-002225.md","text":"https://secwatch.observer/filing/0001178913-23-002225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323002225/0001178913-23-002225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323002225/zk2329883.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:37:31.514176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}